Travere Therapeutics Inc. (TVTX)
NASDAQ: TVTX · Pharmaceutical Preparations · San Diego, CA
Our rating: Positive
Positive reaffirmed at $49.41, moderate conviction, November 3, 2026.
Breaks if: Turn Cautious if revenue growth in either of the next two quarterly reports decelerates below 20% YoY while free cash flow simultaneously reverts to negative — that combination would signal the launch is plateauing before the company achieves self-sustaining economics, removing the central pillar of the Positive call. Conversely, a second approved indication or a meaningful pipeline asset entering a Phase 3 readout within twelve months would support revisiting a step up toward Conviction.
Key figures
| Market value | $4.5B |
|---|---|
| Revenue, last 12 months | $651M |
| Net income, last 12 months | −$122M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | n/a |
| Free cash flow yield | n/a |
| Dividend yield | 0.0% |
| Operating margin | −20.5% |
| Return on equity | −252.7% |
| Beta to the S&P 500 | 1.23 |
| Volatility, annualized | 64.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $225M | 36.2% | $-0.55 | n/a |
| June 30, 2026 | $170M | 48.2% | $-0.37 | n/a |
| March 31, 2026 | $127M | 55.6% | $-0.40 | n/a |
| December 31, 2025 | $130M | 73.4% | $0.03 | n/a |
| September 30, 2025 | $165M | 162.1% | $0.28 | $14M |
| June 30, 2025 | $114M | 111.5% | $-0.14 | n/a |
| March 31, 2025 | $82M | 97.5% | $-0.47 | n/a |
| December 31, 2024 | $75M | 66.0% | $-0.71 | n/a |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.20B: Claude 35%, Gemini 35%, Mistral 85%
- Diluted earnings per share are at least $0.03: Claude 22%, Gemini 10%, Mistral 12%
11 ledger entries and 55 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.